← Back to all signals
RESEARCH PAPER ANALYSIS

Effects of Cha-Cha dance training on fall-related physical performance and cognitive function in patients with Parkinson's disease: A feasibility study.

A 12-week single-group pilot found Cha-Cha dance training improved balance and cognitive test scores in mild–moderate Parkinson’s patients but lacked a control group.

PMID41990889
JournalComplementary therapies in medicine
Publication Date2026-04-15
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

A 12-week single-group pilot found Cha-Cha dance training improved balance and cognitive test scores in mild–moderate Parkinson’s patients but lacked a control group.

WHY IT MATTERS

Research significance

Findings support a feasible, safe non-pharmacological intervention that may reduce fall risk and boost cognition—valuable for symptomatic management and justifying controlled trials, but of limited direct relevance to molecular therapeutic discovery.

ABSTRACT

Source abstract

OBJECTIVES: This study aimed to examine the feasibility and preliminary outcome trends of a 12-week structured Cha-Cha dance training program on balance-related performance, fall-related functional indicators, and cognitive function in patients with mild-to-moderate Parkinson's disease. METHODS: Fourteen participants with PD (Hoehn and Yahr stages 1-3, aged 55-75 years) were recruited. While maintaining their routine pharmacological treatment, participants engaged in a 12-week intervention consisting of two 1.5-hour sessions per week focused on basic Cha-Cha dance steps. Balance function was assessed using the Berg Balance Scale (BBS), the Single-Legged Closed-eyed Standing Test (SCST), and the Timed Up and Go Test (TUGT). Cognitive function was evaluated with the Montreal Cognitive Assessment Scale (MoCA), the Stroop Color-Word Task, and the Flanker Task. This pilot feasibility study used a single-group pre-post design. Pre- and post-intervention data were compared using paired-sample t-tests or Wilcoxon signed-rank tests. RESULTS: After the 12-week intervention, participants showed statistically significant improvements in several balance-related and cognitive outcomes. BBS scores increased significantly (before: 37.57 ± 4.48, after: 40.00 ± 4.47 and p = 0.001); SCST duration on both legs increased significantly (p < 0.05); and TUGT completion time decreased significantly (before: 12.98 ± 1.39 s, after: 10.16 ± 1.05 s and p < 0.001). Total MoCA scores also increased (before: 23.86 ± 2.74, after: 26.07 ± 1.98, p < 0.001), with particularly marked improvements in attention and delayed recall (p < 0.05). In the Stroop task, accuracy improved by 15% and response time decreased by 15%; in the Flanker task, accuracy improved by 27% and response time decreased by 9%. Both accuracy improvements and response time reductions were statistically significant (p < 0.001). CONCLUSION: In this single-group pilot feasibility study, a 12-week structured Cha-Cha dance training program appeared to be a safe and feasible non-pharmacological intervention for individuals with mild-to-moderate PD. The observed changes may indicate preliminary improvements in balance-related performance, fall-related functional indicators, and selected cognitive outcomes; however, in the absence of a control group, these findings should be interpreted as indicative rather than confirmatory evidence. Larger controlled studies are needed to determine efficacy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic